Kostić, V.S. (35239923400)V.S. (35239923400)KostićDjuričić, B.M. (7004603010)B.M. (7004603010)DjuričićČovičković-Šternić, N. (6603691178)N. (6603691178)Čovičković-ŠternićBumbaširević, L. (6506995589)L. (6506995589)BumbaširevićNikolić, M. (7103334614)M. (7103334614)NikolićMršulja, B.B. (7006470637)B.B. (7006470637)Mršulja2025-06-122025-06-121987https://doi.org/10.1007/BF00314109https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023282381&doi=10.1007%2fBF00314109&partnerID=40&md5=b620bae0a7931f96f0653ce63c4976a1https://remedy.med.bg.ac.rs/handle/123456789/1990Depression is frequently encountered in Parkinson's disease and was seen to occur in 14 of 26 patients studied. The levels of 5-hydroxyindoleacetic acid (5-HIAA), the main metabolite of serotonin (5-HT), in CSF samples of the patients were significantly lower than in those of controls. However, within the group of patients the levels of 5-HIAA in CSF samples were significantly lower in the depressive subgroup compared with the non-depressive patients. Moreover, no correlation was recorded between motor disability and depression. The results indicate that disturbed 5-HT metabolism may possibly play a role in Parkinson's disease as a predisposing factor in the development of depression. © 1987 Springer-Verlag.5-Hydroxyindoleacetic acidDepressionHuman cerebrospinal fluidParkinson's disease